Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke

Journal of Molecular Medicine

Volumn 90, Issue 12, 2012, Pages 1459-1471

  Zawadzka, Malgorzata ^a   Dabrowski, Michal ^a   Gozdz, Agata ^a   Szadujkis, Barbara ^a   Sliwa, Marcin ^a   Lipko, Maciej ^a   Kaminska, Bozena ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

CNS inflammation; Gene expression profiling; Immunosuppressants; MAPK signaling; Microglia activation

Indexed keywords

CYCLOOXYGENASE 2; CYCLOSPORIN A; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; INNATE IMMUNITY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CYCLOOXYGENASE 2; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; RATS; STROKE; TACROLIMUS;

EID: 84884211552     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0925-9     Document Type: Article

References (35)

1. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387-1394
2. Aloisi F (2001) Immune function of microglia. Glia 36:165-179
3. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629-640
4. Loddick SA, Rothwell NJ (1999) Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Proc Natl Acad Sci U S A 96:9449-9451
5. Simi A, Tsakiri N, Wang P, Rothwell NJ (2007) Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 35:1122-1126
6. Kaminska B, Gaweda-Walerych K, Zawadzka M (2004) Molecular mechanisms of neuroprotective action of immunosuppressants - facts and hypotheses. J Cell Mol Med 8:45-58
7. Gold BG, Villafranca JE (2003) Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 3:1368-1375
8. Macleod MR, O'Collins T, Horkey LL, Howells DW, Donnan GA (2005) Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713-721
9. Furuichi Y, Maeda M, Matsuoka N, Mutoh S, Yanagihara T (2007) Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp Neurol 204:138-146
10. Furuichi Y, Noto T, Li JY, Oku T, Ishiye M, Moriguchi A, Aramori I, Matsuoka N, Mutoh S, Yanagihara T (2004) Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res 1014:120-130
11. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda Y (1998) Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. Stroke 29:1431-1437
12. Zawadzka M, Kaminska B (2005) A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia 49:36-51
13. Szydlowska K, Gozdz A, Dabrowski M, Zawadzka M, Kaminska B (2010) Prolonged activation of ERK triggers glutamate-induced apoptosis of astrocytes: neuroprotective effect of FK506. J Neurochem 113:904-918
14. Zawadzka M, Kaminska B (2003) Immunosuppressant FK506 affects multiple signaling pathways and modulates gene expression in astrocytes. Mol Cell Neurosci 22:202-209
15. Irizarry R, Gautier RL, Cope L (2002) An R package for analyses of affymetrix oligonucleotide arrays. In: The analysis of gene expression data: methods and software. Springer, New York
16. Storey JD, Tibshirani R (2003) Statistical significance for genome-wide studies. Proc Natl Acad Sci U S A 100:9440-9445
17. Beissbarth T, Speed TP (2004) GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20:1464-1465
18. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M (2009) MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec 292:1902-1913
19. Beuscher HU, Gunther C, Rollinghoff M (1990) IL-1β is secreted by activated murine macrophages as biologically inactive precursor. J Immunol 144:2179-2183
20. Denes A, Pinteaux E, Rothwell NJ, Allan SM (2011) Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis 32:517-527
21. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi S, Raza R, Patel K, Abramson D et al (2000) Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 49:20-26
22. Dusting GJ, Akita K, Hickey H, Smith M, Gurevich V (1999) Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br J Pharmacol 128:337-344
23. Hamalainen M, Lahti A, Moilanen E (2002) Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. Eur J Pharmacol 448:239-244
24. Strestikova P, Otova B, Filipec M, Masek K, Farghali H (2001) Different mechanisms in inhibition of rat macrophage nitric oxide synthase expression by FK 506 and cyclosporin A. Immunopharmacol Immunotoxicol 23:67-74
25. Choi HB, Khoo C, Ryu JK, van Breemen E, Kim SU, McLarnon JG (2002) Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J Neurochem 83:546-555
26. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910
27. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726
28. Kaminska B (2005) MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta Proteomics 1754:253-262
29. Hidding U, Mielke K, Waetzig V, Brecht S, Hanisch U, Behrens A, Wagner E, Herdegen T (2002) The c-Jun N-terminal kinases in cerebral microglia: immunological functions in the brain. Biochem Pharmacol 64:781-788
30. Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-Coyne D, Morath S, Hartung T, Bianchi M, Ghezzi P, Bsibsi M et al (2005) Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J Neurochem 92:1439-1451
31. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, Goetz M, Lucius R, Herdegen T, Hanisch UK (2005) c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 50:235-246
32. Brecht S, Waetzig V, Hidding U, Hanisch UK, Walther M, Herdegen T, Neiss WF (2009) FK506 protects against various immune responses and secondary degeneration following cerebral ischemia. Anat Rec 292:1993-2001
33. Kaminska B, Swiatek-Machado K (2008) Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunolog 4:93-112
34. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ et al (2001) SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 296:312-321
35. Piao CS, Kim JB, Han PL, Lee JK (2003) Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res 73:537-544